/
Infectious Disease
Osteomyelitis
13
Pipeline Programs↗
8
Active Trials↗
10
Companies Involved↗
Osteomyelitis is an emerging landscape with 13 programs across 10 companies. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical11
Phase 1
No programs
Phase 21
Approved
No programs
Analysis
Modality Breakdown
62%
Small molecule
8 of 13 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.
Analysis
Trial Status
27
clinical trials
Completed12 · 44%
Recruiting4 · 15%
Not yet recruiting4 · 15%
Unknown status3 · 11%
Terminated3 · 11%
Withdrawn1 · 4%
Clinical Trials
Trial Activity
27 trials
Drug Delivery Devices for Osteomyelitis
Completed·—·N/A·NCT02968693·51 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)